Half-year report · HY
4483.TEDINET S100X27L
Period2025-04-01 → 2025-09-30
Filed2025-11-12
StandardIFRS
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 47
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥23.1bn | 2025-04-01 → 2025-09-30 | Cons. | Revenue IFRS |
| Revenue | ¥41.7bn | 2024-04-01 → 2025-03-31 | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥18.5bn | 2024-04-01 → 2024-09-30 | Cons. | Revenue IFRS |
| Operating income | ¥4.0bn | 2025-04-01 → 2025-09-30 | Cons. | Operating profit loss IFRS |
| Operating income | ¥3.2bn | 2024-04-01 → 2024-09-30 | Cons. | Operating profit loss IFRS |
| Profit before tax | ¥3.7bn | 2025-04-01 → 2025-09-30 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥8.5bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥3.1bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss before tax IFRS |
| Net income (owners) | ¥2.4bn | 2025-04-01 → 2025-09-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥7.3bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥2.2bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income | ¥2.3bn | 2025-04-01 → 2025-09-30 | Cons. | Profit loss IFRS |
| Net income | ¥2.2bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss IFRS |
| Total assets | ¥152.7bn | at 2025-09-30 | Cons. | Assets IFRS |
| Total assets | ¥143.0bn | at 2025-03-31 | Cons. | Assets IFRS |
| Total assets | ¥136.1bn | at 2024-09-30 | Cons. | Total assets IFRS (5-year summary) |
| Total liabilities | ¥72.8bn | at 2025-09-30 | Cons. | Liabilities IFRS |
| Total liabilities | ¥64.5bn | at 2025-03-31 | Cons. | Liabilities IFRS |
| Net assets / equity | ¥79.9bn | at 2025-09-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥78.5bn | at 2025-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥72.4bn | at 2024-09-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥70.7bn | at 2024-03-31v | Cons. | Equity IFRS |
| Equity (owners) | ¥79.5bn | at 2025-09-30 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥78.0bn | at 2025-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥72.1bn | at 2024-09-30 | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Cash & equivalents | ¥35.9bn | at 2025-09-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥32.2bn | at 2025-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥27.5bn | at 2024-09-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥14.5bn | at 2024-03-31v | Cons. | Cash and cash equivalents IFRS |
| Operating cash flow | ¥6.9bn | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥14.7bn | 2024-04-01 → 2025-03-31 | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥10.8bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Investing cash flow | −¥5.0bn | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥3.5bn | 2024-04-01 → 2025-03-31 | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥4.5bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Financing cash flow | ¥1.8bn | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | ¥6.5bn | 2024-04-01 → 2025-03-31 | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | ¥6.7bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in financing activities IFRS |
| EPS (basic) | ¥36.35 | 2025-04-01 → 2025-09-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥111.34 | 2024-04-01 → 2025-03-31 | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥33.51 | 2024-04-01 → 2024-09-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (diluted) | ¥36 | 2025-04-01 → 2025-09-30 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥110.23 | 2024-04-01 → 2025-03-31 | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥33.18 | 2024-04-01 → 2024-09-30 | Cons. | Diluted earnings loss per share IFRS |
| Equity ratio | 52.1% | at 2025-09-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 54.6% | at 2025-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 52.9% | at 2024-09-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 24
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | segment profit | 2025-04-01 → 2025-09-30 | −¥428m |
| Healthcare Big Datareportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥19.9bn |
| Healthcare Big Datareportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥19.9bn |
| Healthcare Big Datareportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥4.8bn |
| Tele Medicinereportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥3.2bn |
| Tele Medicinereportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥3.2bn |
| Tele Medicinereportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥1.2bn |
| —segment total | revenue | 2025-04-01 → 2025-09-30 | ¥23.1bn |
| —segment total | revenue external | 2025-04-01 → 2025-09-30 | ¥23.1bn |
| —segment total | segment profit | 2025-04-01 → 2025-09-30 | ¥6.0bn |
| Reconciling Itemsreconciling | revenue | 2024-04-01 → 2024-09-30 | −¥21m |
| Reconciling Itemsreconciling | revenue intersegment | 2024-04-01 → 2024-09-30 | −¥21m |
| Reconciling Itemsreconciling | segment profit | 2024-04-01 → 2024-09-30 | −¥401m |
| Healthcare Big Datareportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥15.5bn |
| Healthcare Big Datareportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥15.5bn |
| Healthcare Big Datareportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥21m |
| Healthcare Big Datareportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥3.8bn |
| Tele Medicinereportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥3.1bn |
| Tele Medicinereportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥3.1bn |
| Tele Medicinereportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥1.1bn |
| —segment total | revenue | 2024-04-01 → 2024-09-30 | ¥18.6bn |
| —segment total | revenue external | 2024-04-01 → 2024-09-30 | ¥18.5bn |
| —segment total | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥21m |
| —segment total | segment profit | 2024-04-01 → 2024-09-30 | ¥4.9bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 759
| Item | Context | Value | Unit |
|---|---|---|---|
| Purchase of intangible assets inv cf IFRS | InterimDuration | -677000000 | JPY |
| Payments for loans receivable inv cf IFRS | Prior1InterimDuration | -210000000 | JPY |
| Payments for loans receivable inv cf IFRS | InterimDuration | -350000000 | JPY |
| Collection of loans receivable inv cf IFRS | Prior1InterimDuration | 10000000 | JPY |
| Collection of loans receivable inv cf IFRS | InterimDuration | 811000000 | JPY |
| Purchase of investments inv cf IFRS | Prior1InterimDuration | -594000000 | JPY |
| Purchase of investments inv cf IFRS | InterimDuration | -1000000 | JPY |
| Payments for acquisition of subsidiaries inv cf IFRS | Prior1InterimDuration | -1907000000 | JPY |
| Payments for acquisition of subsidiaries inv cf IFRS | InterimDuration | -4530000000 | JPY |
| Other inv cf IFRS | Prior1InterimDuration | 33000000 | JPY |
| Other inv cf IFRS | InterimDuration | -119000000 | JPY |
| Net cash provided by used in investing activities IFRS | Prior1InterimDuration | -4524000000 | JPY |
| Net cash provided by used in investing activities IFRS | InterimDuration | -5006000000 | JPY |
| Proceeds from short term borrowings fin cf IFRS | Prior1InterimDuration | 300000000 | JPY |
| Proceeds from short term borrowings fin cf IFRS | InterimDuration | － | JPY |
| Repayments of short term borrowings fin cf IFRS | Prior1InterimDuration | -1803000000 | JPY |
| Repayments of short term borrowings fin cf IFRS | InterimDuration | － | JPY |
| Proceeds from long term borrowings fin cf IFRS | Prior1InterimDuration | 12707000000 | JPY |
| Proceeds from long term borrowings fin cf IFRS | InterimDuration | 5744000000 | JPY |
| Repayments of long term borrowings fin cf IFRS | Prior1InterimDuration | -2916000000 | JPY |
| Repayments of long term borrowings fin cf IFRS | InterimDuration | -2304000000 | JPY |
| Repayments of lease obligations fin cf IFRS | Prior1InterimDuration | -561000000 | JPY |
| Repayments of lease obligations fin cf IFRS | InterimDuration | -604000000 | JPY |
| Proceeds from exercise of share acquisition rights fin cf IFRS | Prior1InterimDuration | 22000000 | JPY |
| Proceeds from exercise of share acquisition rights fin cf IFRS | InterimDuration | 42000000 | JPY |
| Dividends paid fin cf IFRS | Prior1InterimDuration | -914000000 | JPY |
| Dividends paid fin cf IFRS | InterimDuration | -1045000000 | JPY |
| Other fin cf IFRS | Prior1InterimDuration | -105000000 | JPY |
| Other fin cf IFRS | InterimDuration | 7000000 | JPY |
| Net cash provided by used in financing activities IFRS | Prior1InterimDuration | 6729000000 | JPY |
| Net cash provided by used in financing activities IFRS | InterimDuration | 1840000000 | JPY |
| Net increase decrease in cash and cash equivalents before effect of exchange rate changes IFRS | Prior1InterimDuration | 12982000000 | JPY |
| Net increase decrease in cash and cash equivalents before effect of exchange rate changes IFRS | InterimDuration | 3687000000 | JPY |
| Cash and cash equivalents IFRS | Prior2YearInstant | 14473000000 | JPY |
| Cash and cash equivalents IFRS | Prior1YearInstant | 32176000000 | JPY |
| Effect of exchange rate changes on cash and cash equivalents IFRS | Prior1InterimDuration | -0 | JPY |
| Effect of exchange rate changes on cash and cash equivalents IFRS | InterimDuration | -0 | JPY |
| Cash and cash equivalents IFRS | Prior1InterimInstant | 27456000000 | JPY |
| Cash and cash equivalents IFRS | InterimInstant | 35863000000 | JPY |
| Revenue from external customers IFRS | Prior1InterimDuration_jpcrp040300-ssr_E35308-000HealthcareBigDataReportableSegmentMember | 15489000000 | JPY |
| Revenue from external customers IFRS | Prior1InterimDuration_jpcrp040300-ssr_E35308-000TeleMedicineReportableSegmentMember | 3058000000 | JPY |
| Revenue from external customers IFRS | Prior1InterimDuration_ReportableSegmentsMember | 18548000000 | JPY |
| Revenue from external customers IFRS | Prior1InterimDuration_ReconcilingItemsMember | － | JPY |
| Revenue from external customers IFRS | Prior1InterimDuration | 18548000000 | JPY |
| Intersegment revenue IFRS | Prior1InterimDuration_jpcrp040300-ssr_E35308-000HealthcareBigDataReportableSegmentMember | 21000000 | JPY |
| Intersegment revenue IFRS | Prior1InterimDuration_jpcrp040300-ssr_E35308-000TeleMedicineReportableSegmentMember | － | JPY |
| Intersegment revenue IFRS | Prior1InterimDuration_ReportableSegmentsMember | 21000000 | JPY |
| Intersegment revenue IFRS | Prior1InterimDuration_ReconcilingItemsMember | -21000000 | JPY |
| Intersegment revenue IFRS | Prior1InterimDuration | － | JPY |
| Revenue IFRS | Prior1InterimDuration_jpcrp040300-ssr_E35308-000HealthcareBigDataReportableSegmentMember | 15511000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |